Study Links Edoxaban to Lower Brain Bleed Risk

Researchers analyzing FDA adverse event data report lower intracranial hemorrhage reporting odds for edoxaban than rivaroxaban.

Updated on Nov. 13, 2026 in Stroke

Isometric editorial illustration of two plain oval tablets, one teal and one ochre, beside a stack of closed grey folders, evoking a comparison of two anticoagulant medicines.
Researchers presenting at the AHA Scientific Sessions in Chicago reported 35% lower reporting odds of intracranial hemorrhage for edoxaban compared with rivaroxaban in FDA adverse event data. AI Illustration. Upload story photo >

A study presented at the AHA Scientific Sessions in Chicago found edoxaban was associated with 35% lower reporting odds of intracranial hemorrhage compared with rivaroxaban. The analysis drew on FDA Adverse Event Reporting System data and included 1,255 edoxaban patients and 147,541 rivaroxaban patients.

Why it matters

Intracranial hemorrhage is a serious complication of anticoagulant therapy, and differences between factor Xa inhibitors could inform prescribing decisions for patients at risk of brain bleeding. The authors called for further investigation of cerebrovascular safety differences between these drugs.

The analysis used FDA adverse event reports, comparing a 1,255-patient edoxaban cohort with a 147,541-patient rivaroxaban cohort, and found a reporting odds ratio of 0.65 for intracranial bleeding. Reporting databases cannot confirm causation, and the study does not resolve whether the Asian share of edoxaban cases (30.8% vs. 4.3%) affects the comparison.

The players

American Heart Association

The American Heart Association is a leading nonprofit organization focused on cardiovascular health and research, and it hosts the Scientific Sessions conference.

U.S. Food and Drug Administration

The U.S. Food and Drug Administration is the federal agency that regulates drugs and maintains the Adverse Event Reporting System used in this analysis.

The details

Researchers compared intracranial hemorrhage reports for rivaroxaban and edoxaban in FAERS data, with a composite endpoint covering cerebral hemorrhage, intracranial hemorrhage, and hemorrhagic stroke. They also evaluated whether the safety signal held despite differences in Asian population representation among reported cases.

Timeline

  1. November 6-9, 2026: AHA Scientific Sessions 2026 held in Chicago, where the study was presented.

Health Landscape

The study relies on FDA Adverse Event Reporting System data, the post-market surveillance network through which regulators and researchers detect drug safety signals after approval. Its findings illustrate how spontaneous reports can reveal differences between anticoagulants, though such reports are subject to reporting bias and cannot establish causation.

Patients taking anticoagulants should not change medication based on this study alone, and any questions about bleeding risk should go to a prescribing clinician. The findings may prompt discussion about which anticoagulant suits an individual's bleeding profile.

The takeaway

Reporting-database comparisons can flag safety differences between drugs, but they point to questions for further study rather than settled answers. Anyone managing anticoagulant therapy should review bleeding risk with their clinician.

Further reading

Explore more on Stroke to see how anticoagulant bleeding risks relate to brain health.

Source note: This article includes information reported by Neurology Advisor.